Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Short summary

A 12- or 24-week regimen of oral daclatasvir plus sofosbuvir achieved a sustained virologic response in 98% of previously untreated patients with HCV genotype 1 and 98% of patients with prior protease inhibitor treatment failure.

AI-generated from the title and abstract; the full text is not read.